COVID-19 Archives -

Vir awarded $1 billion multi-year BARDA influenza contract

Nicole Raleigh BARDA, COVID-19, GSK, influenza, pandemic, prevention, respiratory disease, SARS-CoV-2, sotrovimab, Vir Biotechnology, VIR-2482 0 Comment

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55

Vir awarded $1 billion multi-year BARDA influenza contract

https://pharmaphorum.com/news/vir-awarded-1-billion-multi-year-barda-influenza-contract/

Deep Dive/ Sales and Marketing/ Views & Analysis/ Views and analysis

Unlocking the potential of connected commercialisation solutions

mike.hammerton@pharmaphorum.com Communications and Commercialisation, COVID-19, Deep Dive, Deep Dive: Communications and Commercialisation, Elizabeth Murray, IQVIA, Martin Fox, Stephen How, Steve Ferguson 0 Comment

It is no secret that today’s post-pandemic healthcare landscape in the UK is very different to its pre-pandemic

Unlocking the potential of connected commercialisation solutions

https://pharmaphorum.com/sales-marketing/unlocking-the-potential-of-connected-commercialisation-solutions/

Boy Receiving a Vaccination During a Pandemic

News/ News/ R&D

Pfizer/BioNTech ask FDA for EUA of Omicron bivalent vaccine in children 5+

Nicole Raleigh BioNTech, bivalent, booster shot, Comirnaty, COVID-19, emergency use authorisation, monovalent, Omicron, paediatric, Pfizer, vaccine 0 Comment

A submission to the US Food and Drug Administration (FDA) requesting an Emergency Use Authorization (EUA) of a

Pfizer/BioNTech ask FDA for EUA of Omicron bivalent vaccine in children 5+

https://pharmaphorum.com/news/pfizer-biontech-ask-fda-for-eua-of-omicron-bivalent-vaccine-in-children/

News/ R&D/ Views & Analysis/ Views and analysis

Reconfiguring COVID and influenza vaccines for long-term effectiveness

Jessica Hagen COVID-19, flu, influenza, nucleoprotein, oligoDOM, Osivax, T-cells, technology, vaccines, viruses 0 Comment

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s

Reconfiguring COVID and influenza vaccines for long-term effectiveness

https://pharmaphorum.com/r-d/reconfiguring-covid-and-influenza-vaccines-for-long-term-effectiveness/

R&D/ Views & Analysis/ Views and analysis

Keeping the pandemic at bay with needle-free vaccine delivery

Ben Hargreaves Bharat Biotech, COVID-19, intramuscular, intranasal, needle-free, vaccines 0 Comment

COVID-19 is still circulating and there are fears that further spikes in cases are to be expected in

Keeping the pandemic at bay with needle-free vaccine delivery

https://pharmaphorum.com/r-d/keeping-the-pandemic-at-bay-with-needle-free-vaccine-delivery/

Market Access/ News/ News

Pfizer’s Omicron BA.4/BA.5 vaccine recommended by CHMP

Phil Taylor BioNTech, Comirnaty, coronavirus, COVID-19, COVID-19 vaccine, EU, Omicron, Pfizer 0 Comment

Pfizer and BioNTech’s COVID-19 vaccine targeting Omicron BA.4 and BA.5 has been recommended for authorisation by the EMA’s

Pfizer’s Omicron BA.4/BA.5 vaccine recommended by CHMP

https://pharmaphorum.com/news/pfizers-omicron-ba-4-ba-5-vaccine-recommended-by-chmp/

Medicine doctor hand touching computer interface as medical network connection with modern virtual screen, medical technology network concept

News/ News/ News/ Patients/ R&D

COVID-19 has changed clinical trials for the better, says Medidata

Phil Taylor clinical trials, COVID-19, decentralised clinical trials, digital health, Medidata 0 Comment

The pandemic forced clinical trial sponsors to change their processes, with a more technology-driven approach and, according to

COVID-19 has changed clinical trials for the better, says Medidata

https://pharmaphorum.com/news/covid-19-has-changed-clinical-trials-for-the-better-says-medidata/

News/ Pfizer/ Top pharmaceutical companies

Pfizer bivalent COVID-19 vaccine starts rollout

Nicole Raleigh bivalent vaccine, booster shot, COVID-19, flu season, NHS, Omicron, Pfizer, SARS-CoV-2 0 Comment

The NHS is moving to the next phase of its SARS-CoV-2 vaccination programme, following health secretary Steve Barclay’s

Pfizer bivalent COVID-19 vaccine starts rollout

https://pharmaphorum.com/news/pfizer-bivalent-covid-19-vaccine-starts-rollout-following-jcvi-approval/

Life science leaders sign new ‘Biotech Social Pact’ for Europe

Market Access/ News/ News/ News/ Patients

EMA panel backs COVID-19 vaccines targeting Omicron BA.1

Phil Taylor BioNTech, CHMP, coronavirus, COVID-19, COVID-19 vaccine, EU, Moderna, Omicron, Pfizer 0 Comment

The EMA’s human medicines committee (CHMP) has recommended authorisation of two COVID-19 vaccines from Moderna and Pfizer/BioNTech that

EMA panel backs COVID-19 vaccines targeting Omicron BA.1

https://pharmaphorum.com/news/ema-panel-backs-covid-19-vaccines-targeting-omicron-ba-1/

Trending

COVID-19

Login